18,260 Shares in Insulet Corporation $PODD Acquired by Katamaran Capital LLP

Katamaran Capital LLP bought a new position in Insulet Corporation (NASDAQ:PODD) during the fourth quarter, Holdings Channel.com reports. The fund bought 18,260 shares of the medical instruments supplier’s stock, valued at approximately $5,190,000. Insulet accounts for approximately 3.9% of Katamaran Capital LLP’s investment portfolio, making the stock its 9th largest position.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Whittier Trust Co. of Nevada Inc. raised its holdings in shares of Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 43 shares in the last quarter. Quent Capital LLC bought a new stake in shares of Insulet in the 3rd quarter worth approximately $49,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Insulet in the 3rd quarter worth approximately $49,000. Osterweis Capital Management Inc. bought a new stake in shares of Insulet in the 2nd quarter worth approximately $51,000. Finally, Zions Bancorporation National Association UT raised its holdings in shares of Insulet by 57.3% in the 3rd quarter. Zions Bancorporation National Association UT now owns 173 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 63 shares in the last quarter.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s Q1 results beat expectations, with revenue of $761.7 million and EPS of $1.42, and management raised full-year revenue growth guidance to 21%–23%, reinforcing momentum in its Omnipod diabetes platform.
• Positive Sentiment: The company highlighted strong international Omnipod growth and continued expansion of Omnipod 5 into new markets, which suggests the core business remains healthy. Article Title
• Neutral Sentiment: Recent earnings-call coverage and transcript coverage continued to emphasize improved profitability and upbeat management commentary following the Q1 report. Article Title
• Negative Sentiment: Multiple Wall Street firms cut price targets sharply after the earnings report, including Piper Sandler, JPMorgan, Citigroup, Wells Fargo, Stifel, Raymond James, Canaccord Genuity, Leerink, and others, which likely pressured the shares.
• Negative Sentiment: The stock is also trading well below several recent analyst targets, and the cluster of downgrades/target reductions may be signaling concerns about valuation or the pace of future upside despite the earnings beat.

Insider Buying and Selling at Insulet

In other news, Director Michael R. Minogue bought 2,030 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were acquired at an average cost of $246.23 per share, with a total value of $499,846.90. Following the completion of the transaction, the director directly owned 17,483 shares in the company, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.36% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PODD. The Goldman Sachs Group set a $237.00 target price on shares of Insulet in a report on Thursday. JPMorgan Chase & Co. dropped their target price on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a report on Thursday. Canaccord Genuity Group dropped their target price on shares of Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a report on Thursday. Weiss Ratings upgraded shares of Insulet from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 1st. Finally, Sanford C. Bernstein dropped their target price on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research report on Thursday. Eighteen equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus target price of $257.09.

Insulet Stock Performance

Insulet stock opened at $154.16 on Monday. The firm’s 50 day simple moving average is $211.22 and its 200-day simple moving average is $263.85. The company has a market cap of $10.68 billion, a P/E ratio of 35.85, a price-to-earnings-growth ratio of 1.25 and a beta of 1.20. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. Insulet Corporation has a fifty-two week low of $148.30 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same period last year, the firm posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts predict that Insulet Corporation will post 6.43 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.